Literature DB >> 12499169

Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.

Martin Stürmer1, Schlomo Staszewski, Hans-Wilhelm Doerr, Brendan Larder, Stuart Bloor, Kurt Hertogs.   

Abstract

Zidovudine resistance (ZDV-R) is associated with classic genotypic changes at codons 41, 67, 70, 210, 215, and 219 of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) gene as well as with the multinucleoside resistance (MNR) complexes (Q151M MNR complex; 6-bp insertion/A62V complex). In addition, enhanced resistance to ZDV in the context of the classic ZDV mutations plus the M184V mutation has been associated with additional mutations at positions 208, 211, 214, and 333. In this study we investigated phenotypic ZDV-R determined by a recombinant virus assay (Antivirogram; Virco) in 223 clinical samples in relation to the above genotypic changes. 150 out of 223 clinical samples had the M184V mutation. Phenotypic ZDV-R ranged from 0.3- to 5,338-fold. Sixteen samples (15 with high ZDV-R ranging from 90- to 3,571-fold) contained MNR-associated patterns. Analysis of classic mutational patterns broadly demonstrated increasing ZDV-R with increasing number of ZDV mutations. A comparable correlation was obtained when ZDV-R was analyzed only relative to the T215Y/F mutation. Site-directed mutagenesis experiments investigating the influence of the additional mutations H208Y, R211K, and L214F on ZDV-R resulted in a 7.4- or 21-fold increase in ZDV-R when the R211K/L214F or H208Y/R211K/L214F mutations, respectively, were added to a highly ZDV-R virus. In the clinical sample data set we analyzed, the combination of R211K/L214F appeared most frequently. The H208Y change was detected only in highly ZDV-R viruses, whereas the G333E/D change was distributed equally. All changes were independent of the M184V mutation. A 2.4- or 8-fold increase in ZDV-R was observed in the clinical samples with high ZDV-R containing the R211K/L214F or H208Y/R211K/L214F mutations, respectively. We have shown that the combination of the additional mutations H208Y, R211K, and L214F in HIV-1 RT may influence ZDV-R and should be considered when assessing ZDV-R.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499169      PMCID: PMC149009          DOI: 10.1128/AAC.47.1.54-61.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.

Authors:  J J de Jong; J Goudsmit; V V Lukashov; M E Hillebrand; E Baan; R Huismans; S A Danner; J H ten Veen; F de Wolf; S Jurriaans
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

2.  A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.

Authors:  K Hertogs; S Bloor; V De Vroey; C van Den Eynde; P Dehertogh; A van Cauwenberge; M Stürmer; T Alcorn; S Wegner; M van Houtte; V Miller; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

Authors:  V Miller; A Phillips; C Rottmann; S Staszewski; R Pauwels; K Hertogs; M P de Béthune; S D Kemp; S Bloor; P R Harrigan; B A Larder
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

4.  Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

Authors:  K Van Vaerenbergh; K Van Laethem; J Albert; C A Boucher; B Clotet; M Floridia; J Gerstoft; B Hejdeman; C Nielsen; C Pannecouque; L Perrin; M F Pirillo; L Ruiz; J C Schmit; F Schneider; A Schoolmeester; R Schuurman; H J Stellbrink; L Stuyver; J Van Lunzen; B Van Remoortel; E Van Wijngaerden; S Vella; M Witvrouw; S Yerly; E De Clercq; J Destmyer; A M Vandamme
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 5.  Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

Authors:  N Sluis-Cremer; D Arion; M A Parniak
Journal:  Cell Mol Life Sci       Date:  2000-09       Impact factor: 9.261

6.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

7.  Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.

Authors:  N Yahi; C Tamalet; C Tourrès; N Tivoli; J Fantini
Journal:  J Biomed Sci       Date:  2000 Nov-Dec       Impact factor: 8.410

8.  The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Authors:  V Miller; M Stürmer; S Staszewski; B Gröschel; K Hertogs; M P de Béthune; R Pauwels; P R Harrigan; S Bloor; S D Kemp; B A Larder
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Authors:  M A Winters; K L Coolley; Y A Girard; D J Levee; H Hamdan; R W Shafer; D A Katzenstein; T C Merigan
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

Authors:  B A Larder; S Bloor; S D Kemp; K Hertogs; R L Desmet; V Miller; M Sturmer; S Staszewski; J Ren; D K Stammers; D I Stuart; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

View more
  9 in total

1.  Human immunodeficiency virus polymorphisms and zidovudine resistance.

Authors:  Emanuele Nicastri; Loredana Sarmati; Massimo Andreoni; Saverio G Parisi
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

3.  Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

4.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Sunil S Solomon; Rami Kantor; David Katzenstein; Sathasivam Sivamalar; Nagalingeswaran Kumarasamy; Davey M Smith; Kenneth H Mayer; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

6.  Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Authors:  Anna Schneider; Angela Corona; Imke Spöring; Mareike Jordan; Bernd Buchholz; Elias Maccioni; Roberto Di Santo; Jochen Bodem; Enzo Tramontano; Birgitta M Wöhrl
Journal:  Nucleic Acids Res       Date:  2016-02-04       Impact factor: 16.971

7.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

8.  Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C.

Authors:  Rodrigo D Cunha; Celina M Abreu; Luis M F Gonzalez; Monique Nijhuis; Dorien de Jong; Renato S Aguiar; Adriana O Afonso; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

9.  Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.

Authors:  Pengtao Liu; Yi Feng; Jianjun Wu; Suian Tian; Bin Su; Zhe Wang; Lingjie Liao; Hui Xing; Yinghui You; Yiming Shao; Yuhua Ruan
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.